EPO and Splenomegaly: Additional agents – including thalidomide, hepcidin agonists, and inducers – have been reported to improve ineffective erythropoiesis [21, 22] and, in combination with erythropoietin, to increase hemoglobin levels and reduce splenomegaly in murine models [23].